Xylocor Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.xylocor.com
Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)An Investigational Trial to Evaluate the Effects of the Drug XC001 Delivered Via an Endocardial Delivery Catheter in Subjects With Chronic Angina Caused by Coronary Artery Disease
Not Applicable
Recruiting
- Conditions
- Coronary Artery DiseaseRefractory Angina
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- XyloCor Therapeutics, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT07048808
- Locations
- 🇺🇸
Christ Hospital, Cincinnati, Ohio, United States
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
Phase 1
Completed
- Conditions
- IschemiaCardiovascular DiseasesHeart DiseasesCoronary Artery DiseaseAngina Refractory
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- XyloCor Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04125732
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Cardiology Research Associates, Daytona Beach, Florida, United States
News
No news found